🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Strides Pharma Science Limited STAR NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.strides.com

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.

READ MORE ›
₹1,111.80
+42.94% 1Y

Market & Price

Market Cap
₹10,247.76 Cr
Current Price
₹1,111.80
High / Low (52W)
₹1,188.10 / ₹777.78
Beta
0.31

Valuation

Stock P/E
18.42
Industry PE
37.60
Forward P/E
11.46
PEG Ratio
-
Book Value
₹299.06
Price to Book
3.72
P/S
2.11
EV/EBITDA
12.79
Dividend Yield
0.36%

Profitability & Returns

ROCE
21.01%
ROE
20.03%
ROA
6.96%
Profit Margin
11.45%
Op Margin
14.09%
EPS (Latest Qtr)
₹13.77
EPS (TTM)
₹60.37

Balance Sheet & Liquidity

Debt/Equity
0.56
Quick Ratio
0.52
Current Ratio
1.25
Debt
₹1,757.98 Cr
Total Assets
₹6,927.23 Cr
Current Assets
₹3,613.34 Cr
Working Capital
₹717.85 Cr

Ownership

Promoter Holding
30.83%
Chg in Prom Hold
-
FII / Inst Holding
29.73%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹11,836.17 Cr
Total Revenue (TTM)
₹4,858.68 Cr
EBITDA
₹925.29 Cr
Free Cash Flow
₹32.17 Cr
Operating Cash Flow
₹702.52 Cr
Shares Outstanding
₹9.22 Cr
Gross Margin
59.69%
Payout Ratio
6.63%

Growth (CAGR)

Revenue 5Y
10.43%
Profit 5Y
124.83%
Revenue (YoY)
11.20%
Earnings (YoY)
54.40%

PROS

  • Strong return on equity of 20.0%.
  • Healthy ROCE of 21.0%.
  • Compounding revenue at 10.4% over 5 years.
  • Profit CAGR of 124.8% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 STAR Strides Pharma Science Limited NSEPHARMA 1,111.80 18.42 ₹10,247.76 Cr 0.36% 21.01% 20.03% 10.43% 124.83%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026
Revenue 1,153.67 Cr1,190.39 Cr1,119.74 Cr1,194.65 Cr1,323.47 Cr
Cost of Revenue 480.12 Cr498.97 Cr444.28 Cr462.94 Cr536.25 Cr
Gross Profit 673.54 Cr691.43 Cr675.45 Cr731.71 Cr787.23 Cr
Operating Expenses 511.65 Cr522.42 Cr506.26 Cr546.38 Cr600.77 Cr
Operating Income 161.89 Cr169.01 Cr169.19 Cr185.32 Cr186.46 Cr
EBITDA 214.45 Cr205.56 Cr218.39 Cr339.48 Cr242.88 Cr
Interest Expense 52.18 Cr50.32 Cr47.46 Cr43.38 Cr41.58 Cr
Pretax Income 113.84 Cr106.38 Cr122.04 Cr245.47 Cr148.05 Cr
Tax Provision 23.80 Cr20.76 Cr16.45 Cr37.35 Cr18.77 Cr
Net Income 87.95 Cr82.19 Cr99.61 Cr202.11 Cr126.94 Cr
Diluted EPS 9.558.9210.8121.9213.77

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -3,607.67 Cr3,730.02 Cr4,565.34 Cr4,858.68 Cr
Cost of Revenue -1,745.85 Cr1,883.55 Cr1,979.97 Cr1,958.73 Cr
Gross Profit -1,861.82 Cr1,846.47 Cr2,585.37 Cr2,899.95 Cr
Operating Expenses -1,718.94 Cr1,525.39 Cr1,974.82 Cr2,177.06 Cr
Operating Income -142.88 Cr321.08 Cr610.55 Cr722.89 Cr
EBITDA -174.64 Cr344.40 Cr928.03 Cr1,049.63 Cr
Interest Expense -217.59 Cr238.51 Cr248.85 Cr178.54 Cr
Pretax Income --286.20 Cr-114.79 Cr486.92 Cr668.69 Cr
Tax Provision --55.30 Cr29.11 Cr77.52 Cr94.19 Cr
Net Income --202.63 Cr-70.61 Cr3,593.45 Cr556.19 Cr
Diluted EPS -51.28-22.49-7.76390.50-

Compounded Sales Growth

5 Years:10.43%
1 Year:11.20%

Compounded Profit Growth

5 Years:124.83%
1 Year:54.40%

Stock Price Performance

1 Year:+42.94%
6 Months:+25.02%
3 Months:+27.10%
1 Month:+5.54%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -6,638.42 Cr5,839.76 Cr6,048.73 Cr6,927.23 Cr
Current Assets -3,245.94 Cr2,972.49 Cr3,101.68 Cr3,613.34 Cr
Cash & Equivalents -303.50 Cr161.02 Cr112.56 Cr188.70 Cr
Inventory -1,146.51 Cr1,126.24 Cr1,277.57 Cr1,634.79 Cr
Receivables -1,299.40 Cr1,141.87 Cr1,202.94 Cr1,288.96 Cr
Total Liabilities -4,465.54 Cr3,768.05 Cr3,462.26 Cr3,777.89 Cr
Current Liabilities -2,990.20 Cr2,879.26 Cr2,591.52 Cr2,895.49 Cr
Long Term Debt -1,139.79 Cr671.50 Cr571.24 Cr552.32 Cr
Total Debt -3,029.57 Cr2,516.86 Cr1,879.63 Cr1,757.98 Cr
Total Equity -2,212.26 Cr2,125.57 Cr2,551.83 Cr3,107.57 Cr
Shares Outstanding -9.03 Cr9.19 Cr9.22 Cr9.22 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -44.41 Cr701.07 Cr684.37 Cr702.52 Cr
Investing Cash Flow -302.47 Cr-150.25 Cr-89.69 Cr-173.04 Cr
Financing Cash Flow --213.92 Cr-693.32 Cr-642.58 Cr-453.41 Cr
Capital Expenditure --94.94 Cr-118.15 Cr-247.50 Cr-417.94 Cr
Free Cash Flow --50.53 Cr582.91 Cr436.88 Cr284.58 Cr
Net Change in Cash -132.96 Cr-142.51 Cr-47.90 Cr76.07 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -51.6%49.5%56.6%59.7%
Operating Margin % -4.0%8.6%13.4%14.9%
Net Margin % --5.6%-1.9%78.7%11.4%
ROE % --9.2%-3.3%140.8%17.9%
ROCE % -3.9%10.8%17.7%17.9%

Shareholding Pattern

Insiders
30.83%
Institutions
29.73%
Public Float
42.98%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for STAR

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space